CCI dismisses complaint against Cipla, BCDA

21 May 2019 Evaluate

The Competition Commission of India (CCI) has dismissed a complaint against Cipla and the Bengal Chemist and Druggists Association (BCDA) over alleged non-supply of medicines.

While dismissing the complaint, the fair-trade regulator said the complainant tried to give a commercial dispute between him and Cipla a colour of competition issue. The complainant had alleged that despite placement of repeated orders, Cipla had stopped the supply of medicines at the behest of BCDA.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1403.90 4.55 (0.33%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.85
Dr. Reddys Lab 5812.50
Cipla 1403.90
Zydus Lifesciences 1104.45
Lupin 1661.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.